The real economics of specialty pharmacy: What your specialty drug trend isn’t telling you
A specialty drug shows up on your trend report with a six-figure price tag. You assume that’s the drug cost. But in specialty pharmacy, the story is often more complex.
Take the recent case of a state-sponsored plan that was charged $138,000 a year for a generic cancer drug, which had a wholesale cost of $14,000.1 Nothing in the system was designed to flag it. It simply got absorbed into the trend.
“Specialty drug pricing is often folded inside a much larger deal — and what you can’t see, you can’t manage,” says Jonah Houts, vice president of account management, contracting and strategy at Walgreens Specialty Pharmacy.
As specialty drug costs grow and benefit designs become more complex, payers who can see the full picture — across pricing, rebates, and patient outcomes — are better positioned to manage costs before they escalate.
Understanding the Full Picture
Over the past decade, specialty pharmacy has evolved significantly — growing more complex, consolidated, and central to patient care. Today, the three largest pharmacy benefit managers oversee roughly 80% of all U.S. prescription drug claims, and each is owned by or owns a major health insurer. Within these structures, a single corporate parent may negotiate drug pricing, manage the pharmacy benefit, dispense medications, and insure the patient.
This level of integration offers efficiencies of scale — but it also makes it more difficult for payers to see how individual parts of the specialty benefit contribute to overall costs and patient outcomes.
As specialty costs continue to rise, payers and plan sponsors need to look beyond the drug price itself. The factors driving total spend run deeper, from benefit design and pricing transparency to the patient’s experience after a prescription is filled — including therapy initiation, adherence, and avoidable complications that never appear on a pharmacy bill.
Payers are increasingly turning to independent partners like Walgreens Specialty Pharmacy, with a model designed to support cost transparency and patient outcomes.
Why Independence Matters
In traditional pharmacy benefit models, retail, mail order, specialty pharmacy, and rebate management are typically packaged together. When all four are bundled, the true cost of any single component becomes difficult to evaluate independently. At the same time, rebate structures built into those arrangements can create incentive dynamics that don’t always align with a plan sponsor’s cost goals.
An independent specialty pharmacy partner operates differently.
“Our independence means we’re payer-agnostic,” says Houts. “We can build and administer a specialty pharmacy benefit without respect to who the third-party payer is on the other end.”
Without rebate relationships or formularies to maintain, Walgreens works exclusively for you — sourcing the best price for each drug and giving plan sponsors a clear, direct view of their specialty spend.
A Flexible, Plug-and-Play Solution
Walgreens Specialty Pharmacy can structure deals around cost-plus pricing — where plans see exactly what Walgreens pays for a drug — paired with a flat dispensing fee. This eliminates the percentage-based markups that can inflate specialty costs.
“We’re constantly reporting through the entire cycle so no one is surprised that a $1,000 drug became a $10,000 drug simply because a guarantee allowed it to be so,” says Houts.
Independence also expands patient access. Walgreens operates more than 250 community-based specialty pharmacies embedded in local care ecosystems, near hospitals and provider offices, with 70% of providers within 25 miles of a location. Each site is staffed by specialized care teams who provide in-person support, prior authorization assistance and personalized clinical programs that reduce delays, support adherence, and keep therapy on track from the first fill forward.
Walgreens can also ship specialty medications to any of more than 8,000 retail locations nationwide, giving plan sponsors an omnichannel model that meets patients wherever they are. “Particularly when a medication is needed same day, we can meet those needs,” says Houts.
Staying Ahead of Hidden Costs
Once a specialty prescription is received, payers enter one of the most critical — and least visible — windows in specialty care. Every missed dose, unmanaged side effect, delayed start, and storage mishap is a cost payers may eventually incur: avoidable hospitalizations, unnecessary therapy switches, and drug waste that never appear on a pharmacy bill.
“The high costs often don’t come from the drug,” says Rachel K. Anderson, PharmD, CSP with Walgreens Specialty Pharmacy. “They come from what happens when the drug isn’t taken correctly, consistently, or at all.”
“Adherence is a prime example. Often viewed narrowly as a refill metric, it’s a dynamic outcome shaped by continuous engagement,” says Anderson. Walgreens Specialty Pharmacy anticipates adherence barriers through our proprietary clinical platform — side effects, affordability concerns, confusion about therapy — and addresses them before they escalate.
The stakes are highest in the most complex disease states. In oncology, even small adherence gaps can lead to dose reductions or patient drop off. In chronic inflammatory diseases, patients not taking their medication correctly may experience costly flares or switch therapies unnecessarily. In rare diseases, missed infusions can mean significant drug waste and rapid clinical decline.
One way Walgreens Specialty Pharmacy addresses these risks is through Specialty 360, its patient-facing care model that supports patients from the moment a prescription is received through the entire duration of therapy. Dedicated disease-specific clinical teams manage everything from benefits verification and prior authorization to patient education and ongoing clinical monitoring.
“Payers can underestimate how much value is created when the model shifts from reactive dispensing to proactive patient-centered care,” Anderson says. “The most meaningful interventions are often ones that prevent problems entirely — so they never show up in traditional metrics.”
The Future of Specialty Pharmacy Is Patient-Centered
Behind all the complexity of specialty pharmacy — the formularies, the cost-sharing mechanisms, pricing negotiations — there is a patient who is sick and needs access to medicine. For Houts, that is where the conversation must ultimately head.
As specialty medications grow more complex and costly, the demands on the entire pharmacy ecosystem are intensifying. Patients managing these therapies need more support than ever, and payers are increasingly looking to their pharmacy partners to provide it. For Houts, this is the industry’s defining challenge. “You can build all the complex, rigorous systems around your specialty pharmacy drug spend,” he says. “But if you’re not taking care of the patient, it all falls apart.”
For Walgreens, that patient-centered approach is already built into how it operates. As payers look beyond the drug price to understand what truly drives specialty spend, the model offers something increasingly valuable: the visibility and patient-level insights needed to better manage costs and outcomes over the long term.
To learn more, visit Walgreens Specialty Pharmacy online.
Sources:
1 US House of Representatives, Committee on Oversight and Accountability. The Role of Pharmacy Benefits Managers in Prescription Drug Markets Part III: Transparency and Accountability. 118th Congress. July 23, 2024.
